BMI trajectories and their relation to medication, comorbidities, and healthcare service use among people with type 2 diabetes mellitus
Authors' conclusion
These findings reveal considerable heterogeneity in long-term outcomes among people with T2D and highlight the need for continuous monitoring and targeted support to maintain metabolic control and manage comorbidity burden.
Study context
- Population
- Adults with T2D diagnosed in North Karelia (2011–2014), followed until 2024
- Participants
- 3,539 adults
- Exposure
- BMI trajectory classes: stable vs increasing vs decreasing
- Outcome
- BMI trajectories after T2D diagnosis
Methodological detailsgrowth mixture modeling
- Growth mixture modeling
Main finding
As reported in the abstract
BMI trajectory classes
Observational data: associations, not effects.
Further findings
HbA1c and LDL-C measurement activity
- Lowest in the decreasing class
GLP-1 RA use
- Varied over time; peaked in the decreasing class in 2015 and in the increasing class in 2024
Comorbidities
- Increased in all classes; increasing class accumulated more chronic kidney and urinary tract diseases, obesity-related diagnoses, sleep disorders and chronic lower respiratory diseases; decreasing class had higher prevalence of dementia and cardiovascular and pulmonary diseases
Healthcare utilization
- Highest in the decreasing class
Original publication
BMI trajectories and their relation to medication, comorbidities, and healthcare service use among people with type 2 diabetes mellitus. Diabetes Res Clin Pract. Published 22 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →